Kardigan Planning for $350 Million IPO Raise: Report
Key Takeaways
- Kardigan’s offering proposes 23.3 million shares at $14–$16, targeting ~$350 million gross proceeds and an implied ~$1.3 billion valuation amid a reopened biotech IPO window.
- Danicamtiv, an oral cardiac myosin activator licensed from BMS/MyoKardia, is in the adaptive Phase 2b/3 KINSHIP-DCM trial for MYH7/TTN-driven genetic dilated cardiomyopathy.
Kardigan has filed to raise approximately $350 million in an IPO that would value the cardiovascular biotech at roughly $1.3 billion, expecting that its three late-stage programs can attract investors in a market still riding a biotech IPO wave.
Kardigan moved to capitalize on renewed investor appetite for biotech Initial Public Offerings (IPO)s, filing plans to sell 23.3 million shares at between $14 and $16 each, which would raise approximately $350 million and value the company at roughly $1.3 billion.1
The timing of Kardigan’s IPO follows a record-breaking week for biotech public offerings, with
Despite the favorable climate, Kardigan's proposed offering is not expected to rank among the year's three largest biotech IPOs, which have been claimed by Parabilis, Kailera Therapeutics, and Generate:Biomedicines respectfully. The company plans to list on Nasdaq under the ticker "KARD."1
If the IPO closes as proposed, Kardigan would represent a bet on cardiovascular precision medicine at a moment when investor attention in the biotech IPO market has been largely concentrated in oncology and metabolic disease.
What is in Kardigan's pipeline?
Kardigan is advancing three late-stage cardiovascular programs, each licensed from established industry sources, in indications where no approved therapies currently exist.1
The company’s lead asset, danicamtiv, is an oral cardiac myosin activator originally discovered at MyoKardia and subsequently licensed from BMS following its acquisition of that company.2 The drug targets genetic dilated cardiomyopathy caused by pathogenic variants in MYH7 and TTN, the most common sarcomeric gene variants, and is designed to restore myosin function and directly address the underlying sarcomeric defects that impair muscle contraction and force generation. Danicamtiv has been evaluated in 10 completed clinical studies and is currently being assessed in the Phase 2b/3 adaptive, randomized, placebo-controlled Kinship-DCM trial.1,2
Kardigan’s second lead program ataciguat is an oral once-daily soluble guanylate cyclase activator licensed from Sanofi and the Mayo Clinic. It targets valvular interstitial cells to slow the osteogenic and calcific remodeling that drives disease progression in calcific aortic valve stenosis, a condition for which no approved pharmacological treatments exist.3 Ataciguat is currently being studied in the Phase IIb Katalyst-AV trial.1,3
The final key asset is tonlamarsen, a liver-directed antisense oligonucleotide licensed from Ionis Pharmaceuticals, administered once monthly via subcutaneous injection.3 It targets hepatic angiotensinogen for blood pressure management in patients with acute severe hypertension following hospitalization and is being evaluated in the Phase II KardinalL-ASH trial.1,4
What is the Prolaio platform?
Alongside its drug pipeline, Kardigan owns Prolaio, a proprietary data and analytics platform that integrates third-party wearable sensors with AI-driven analytics to collect continuous physiologic data from patients in their daily lives outside of clinical settings.1 The platform includes Class I and Class II FDA-regulated devices with 510(k)-cleared algorithms, and is designed to enable higher-frequency real-world data collection than traditional clinical trials allow.1
Kardigan says this longitudinal data capability supports more efficient trial design, faster proof-of-concept timelines, and the development of novel digital clinical endpoints, though the company acknowledges there is no guarantee the platform will deliver accelerated timelines or improve the probability of success.1
Sources
- Amendment No. 1 to Form S-1 Registration Statement Under The Securities Act of 1933 Kardigan, Inc. United States Security and Exchange Commission June 11, 2026
https://www.sec.gov/Archives/edgar/data/2123613/000119312526266629/d107928ds1a.htm - A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy (KINSHIP-DCM) National Library of Medicine June 3 , 2026
https://clinicaltrials.gov/study/NCT07210723 - Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study (KATALYST-AV) National Library of Medicine May 6, 2026
https://clinicaltrials.gov/study/NCT07001800 - Study of Efficacy and Safety of Tonlamarsen in Participants With Acute Severe Hypertension Recently Discharged From the Hospital (KARDINAL-ASH) National Library of Medicine May 6, 2026
https://clinicaltrials.gov/study/NCT07511361
Related Content
